MARK4 controls ischaemic heart failure through microtubule detyrosination

Area of Science:

• Cardiology
• Molecular Biology
• Cell Biology

Background:

• Myocardial infarction (MI) is a leading cause of death, often leading to heart failure.
• Current inotropic therapies for heart failure have significant risks and limited efficacy.
• Microtubule detyrosination is a newly identified regulator of cardiomyocyte contractility.

Purpose of the Study:

• To investigate the role of microtubule-affinity regulating kinase 4 (MARK4) in cardiac function post-myocardial infarction.
• To explore MARK4's mechanism in regulating cardiomyocyte contractility and microtubule detyrosination.

Main Methods:

• Utilized a mouse model of acute myocardial infarction.
• Assessed cardiac function, including left ventricular ejection fraction, infarct size, and cardiac remodeling.
• Investigated the molecular mechanism involving MARK4, MAP4, VASH2, and α-tubulin detyrosination in cardiomyocytes.

Main Results:

• MARK4 deficiency significantly preserved left ventricular ejection fraction after MI in mice.
• MARK4 deficiency did not alter infarct size or cardiac remodeling.
• MARK4 promotes cardiomyocyte contractility by phosphorylating MAP4, enhancing VASH2-mediated microtubule detyrosination.

Conclusions:

• MARK4 plays a critical role in regulating cardiac inotropy through microtubule detyrosination.
• Targeting MARK4 represents a promising therapeutic strategy for improving cardiac function after myocardial infarction.